For inhibiting complement activation due to FH deficiency, drug compounds targeting C3, FB, C5, FP, C3b, C3bB, and C3-convertase at 90% inhibition are predicted to be efficacious in reducing disease severity. Here, C5 is linked to hyperinsulinemic hypoglycemia, familial, 4.